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We appreciate the feedback provided, and
would like to address the highlighted
concerns. The authors suggest that the
included studies represent a small sample of
the available literature. The studies included in
our review were selected in a systematic and
unbiased manner using comprehensive search
of the published literature and pre-defined
eligibility criteria. We do acknowledge that
this economic analysis, like many others, is
limited by the available data [1–4]. Many
cost-effectiveness analyses use data from a
single primary investigation, or combine cost
an efficacy data from several identified studies,
which is similar to our approach [2, 4–6].
As suggested by the authors, we accounted
for the number of injections in our costing of
each product. Despite this, the assumption that
the authors of the editorial have made in their
calculations assumes that all products have
comparable efficacy, which is not accurate.
Cost-effectiveness analyses consider differences
in both cost and effectiveness. Assuming that
the effectiveness is comparable is a
cost-minimalization analysis, which is not
appropriate when there are differences in both
cost and effectiveness among the therapies
compared. Utility scores derived from our
included studies [7–11], as well as recent
meta-analyses [12, 13], demonstrate
considerable differences in efficacy that have
been suggested to be due to product
characteristic differences, such as molecular
weight and production process. For this
reason, we do not believe the authors’
calculations looking strictly at product costs is
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an accurate depiction of the cost-effectiveness
of the various hyaluronic acid products.
The authors of the editorial have provided
detailed calculations comparing the cost
differences between Synvisc-One and Euflexxa
to demonstrate the missing information for
Synvisc-One from our analysis. While this
comparison suggests a cost savings with
Synvisc-One over Euflexxa, it does not provide
a complete picture, as utility data, and other
costing data, are not considered. As mentioned
above, in cost-effectiveness analyses, both cost
and outcomes need to be included. For this
reason, Synvisc-One was not eligible for
inclusion in our analysis. If future
investigations provide sufficient data to
determine utility score improvements
following the use of Synvisc-One, there would
be sufficient information to include this
product in an update of our analysis. To
continue on this point, our analysis does not
dispute that Supartz and Hyalgan are a less
expensive option than Euflexxa; however, as
stated above, the calculation you have provided
does not consider the ‘‘effectiveness’’ portion of
the cost-effectiveness analysis. The incremental
cost-effectiveness ratio (ICER) values
demonstrate the cost of additional efficacy
provided by Euflexxa; as although Hyalgan
and Supartz are less expensive, they also have
demonstrated smaller QALY improvement
estimates than Euflexxa.
We aimed to include as many comparators as
reasonably possible to have comparable utility
data. We were transparent in our methods when
describing that the Euflexxa utility scores were
obtained from a previous cost-effectiveness
analysis conducted on the Altman trial. We do
not believe that the utility scores extrapolated
from the Hatoum study are substantially
different from the other products; for example,
Euflexxa and Synvisc were shown to have
similar baseline values differing by 0.079
QALY. Despite us believing that the utility
scores from the Hatoum study provided
comparable results to the other studies, we
conducted utility score sensitivity analyses to
address the potential variability that you have
highlighted. All results were calculated multiple
times under a number of different sensitivity
analysis scenarios to provide a more robust
depiction of the results of our analysis.
There is always uncertainty regarding
heterogeneity whenever multiple studies are
compared, as stated by the authors of the
editorial. This is an inherent limitation in not
only our cost-effectiveness analysis, but in
systematic reviews and meta-analyses as well.
To account for the potential differences in
utility scores as a result of study methodology
heterogeneity, sensitivity analyses were
conducted as a measure of ensuring that we
considered potential differences from the utility
score point estimates derived from the included
studies. The authors are correct in stating that
the inclusion of HRQoL measures within
clinical trials would aid in conducting future
cost-effectiveness analyses, as future authors
would not require the data conversions used
in our study to derive utility scores.
Unfortunately, studies of IA-HA use for knee
OA have not typically adopted this approach,
which, therefore, makes our approach an
appropriate alternative that is well
documented and utilized in cost-effective
analyses [14, 15].
We agree there are a very large number of
indirect costs that could be considered when
comparing products; however, it is often
difficult to accurately estimate the differences
in these costs within each group. While we
aimed to address as many factors as possible, we
also ensured to use a conservative and broad
sensitivity analysis of costs to ensure that any
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potential real-world cost differences may be
accounted for.
We appreciate the critical review of our work,
and think that the author has brought up many
important points. We agree and welcome future
investigations to aid in effort to assist patients,
physicians, and healthcare systems in choosing
the best care for their patients with OA of the
knee. We would like to thank the authors of the
editorial for providing their feedback on our
article.
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